A citation-based method for searching scientific literature

Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni, Hiroshi Hiai, Wataru Mizunoya, Tohru Fushiki, Jens Juul Holst, Mitsuhiro Makino, Akira Tashita, Yukari Kobara, Yoshiharu Tsubamoto, Takayoshi Jinnouchi, Takahito Jomori, Yutaka Seino. Nat Med 2002
Times Cited: 610



Alma Fulurija, Thomas A Lutz, Katja Sladko, Melania Osto, Peter Y Wielinga, Martin F Bachmann, Philippe Saudan. PLoS One 2008
Times Cited: 71




List of shared articles



Times cited


Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
Jason A West, Anastasia Tsakmaki, Soumitra S Ghosh, David G Parkes, Rikke V Grønlund, Philip J Pedersen, David Maggs, Harith Rajagopalan, Gavin A Bewick. PLoS One 2021
1


Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A Killion, Shu-Chen Lu, Madeline Fort, Yuichiro Yamada, Murielle M Véniant, David J Lloyd. Endocr Rev 2020
19


Effects of gastric inhibitory polypeptide (GIP) immunoneutralization on mouse motor coordination and memory.
Claire Y Zhang, Michael O Boylan, Hiroyuki Arakawa, M Michael Wolfe. Peptides 2020
0

Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review.
Maria Buur Nordskov Gabe, Wijnand J C van der Velden, Florent Xavier Smit, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde. Peptides 2020
7

The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.
Daniela Regazzo, Mattia Barbot, Carla Scaroni, Nora Albiger, Gianluca Occhi. Rev Endocr Metab Disord 2020
5


How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J Samms, Matthew P Coghlan, Kyle W Sloop. Trends Endocrinol Metab 2020
23

Incretins in obesity and diabetes.
Chee W Chia, Josephine M Egan. Ann N Y Acad Sci 2020
19

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
Natasha C Bergmann, Lærke S Gasbjerg, Sebastian M Heimbürger, Liva S L Krogh, Flemming Dela, Bolette Hartmann, Jens J Holst, Lene Jessen, Mikkel B Christensen, Tina Vilsbøll,[...]. Diabetes Care 2020
12

Insights into incretin-based therapies for treatment of diabetic dyslipidemia.
Kerstin Stemmer, Brian Finan, Richard D DiMarchi, Matthias H Tschöp, Timo D Müller. Adv Drug Deliv Rev 2020
6

Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus.
Yukiko Fu, Kentaro Kaneko, Hsiao-Yun Lin, Qianxing Mo, Yong Xu, Takayoshi Suganami, Peter Ravn, Makoto Fukuda. Endocrinology 2020
6

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
60